Multiple CE-IVD marked immunoassays for antibody detection to SARS-CoV-2 (COVID 19) now available

Request more information on sales.uk@werfen.com – or contact your local Werfen Ltd representative

NovaLisa® SARS-CoV-2 (COVID-19) ELISA for Coronavirus Antibody Testing

The novel antibody tests for IgG, IgM, and IgA are intended for the qualitative detection of IgG, IgA and IgM antibodies to SARS-CoV-2 virus in human serum to aid in the diagnosis of Coronavirus (COVID-19) and provide information about past exposure to the virus. Initial testing on more than 300 samples demonstrated high sensitivity and specificity ultimately providing valuable information on individual patients as well as larger cohorts. The assays are compatible with many open high-throughput automation platforms and can therefore provide important cost-efficient testing capacity at scale.

• Separate detection of IgG, IgA, and IgM antibodies to SARS-CoV-2
• A valuable tool to assess the immune response of the patient  during and after the infection
• Simple workflow, fast results
• Ease of use on any open ELISA automation platform
• Total incubation under 2 hours
• CE marking IVD